Endovastec(SH:688016) Sou Hu Cai Jing·2025-07-02 11:20Group 1 - The core business of the company is the research, production, and sales of interventional medical devices for aorta and peripheral blood vessels [2] - The company has received several awards, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2] - The latest financial report for Q1 2025 shows a revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% [2] Group 2 - The company's current stock price is 94.54 yuan, with a rolling PE ratio of 26.04 times and a total market capitalization of 11.653 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 51.29 times, with a median of 37.02 times, placing the company at the 57th position [1][3] - As of March 31, 2025, the number of shareholders has increased to 18,176, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]